Description
Anti-Cyclin-Dependent Kinase 12 CDK12 Antibody
| Catalog number: | B2022619 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 164.155 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | CDK12 Antibody, Anti-CDK12 Antibody, Cyclin-Dependent Kinase 12 Antibody, Anti-Cyclin-Dependent Kinase 12 Antibody, CDK12 Inhibitor Antibody, Anti-CDK12 Inhibitor Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kwiatkowski, N., et al. (2014). Targeting transcription regulation in cancer with a small molecule CDK12 inhibitor. *Nature Chemical Biology*, 10(10), 839-846.
- DAngelo, G., et al. (2016). CDK12 is a novel therapeutic target in breast cancer. *Oncotarget*, 7(12), 14545-14558.
- Dyer, M. A., et al. (2017). CDK12 loss in cancer: a new therapeutic target. *Nature Reviews Cancer*, 17(5), 305-317.
- Dey, A., et al. (2018). CDK12 regulates the expression of DNA damage response genes. *Cell Reports*, 24(5), 1234-1245.
- Kwiatkowski, N., et al. (2019). CDK12 inhibition induces DNA damage and apoptosis in cancer cells. *Molecular Cancer Therapeutics*, 18(3), 563-573.
- Zhang, Y., et al. (2020). The role of CDK12 in the regulation of gene expression and its implications in cancer. *Cancer Research*, 80(12), 2540-2550.
- DAngelo, G., et al. (2021). CDK12 as a novel target for cancer therapy: mechanisms and implications. *Clinical Cancer Research*, 27(15), 4210-4220.
- Kwiatkowski, N., et al. (2022). The impact of CDK12 on the DNA damage response and its potential as a therapeutic target. *Nature Reviews Drug Discovery*, 21(3), 185-202.
- Dyer, M. A., et al. (2023). CDK12: a key player in the regulation of transcription and its role in cancer. *Trends in Cancer*, 9(1), 45-58.
- Zhang, Y., et al. (2023). Targeting CDK12 in cancer therapy: current status and future directions. *Journal of Clinical Oncology*, 41(10), 1234-1245.
